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Using 98 clinical methicillin-susceptible Staphylococcus aureus isolates of known -lactamase (Bla) type, we
found a pronounced inoculum effect for cephalexin (mostly Bla type A and C strains), a mild inoculum effect
for cephalothin (especially types B and C), and no inoculum effects for ceftriaxone and cefuroxime. Ceftobi-
prole showed the lowest MICs at a high inoculum but with a slight increase for Bla-positive versus Bla-negative
strains. Since a potential therapeutic effect associated with a cephalosporin inoculum effect has been described,
further studies are warranted.
Strains of methicillin-susceptible Staphylococcus aureus
(MSSA) are still responsible for the majority of severe staph-
ylococcal infections, as shown in a recent international study in
which 85.2% of S. aureus strains producing native valve endo-
carditis were susceptible to methicillin (11). About 90% of the
MSSA isolates produce one of four variants of -lactamase(s)
(Bla) (16) identified as type A, B, C, or D (9, 13, 22). Each of
these staphylococcal Bla types has a specific substrate profile
(21). These severe MSSA infections are often treated with
cephalosporins, and even though cephalosporins are regarded
as generally stable in the presence of staphylococcal Bla, it was
shown early on that when tested at higher inocula, some ceph-
alosporins were hydrolyzed by certain types of Bla (inoculum
effect) (10). It was not until the 1990s, when the kinetics of
hydrolysis among the four types of staphylococcal Bla were
reported, that the classification of cephalosporins as Bla stable
or labile was considered an oversimplification of the cephalo-
sporin-Bla interaction (23). However, the actual effect of each
type of staphylococcal Bla on the in vitro activity of different
cephalosporins, measured by the presence of an inoculum ef-
fect, has not been clearly defined. Strains producing a large
amount of the Bla enzyme and/or showing high MICs when a
large inoculum is used have been associated with clinical fail-
ures in patients suffering high-inoculum staphylococcal disease
(e.g., cefazolin in the treatment of endocarditis caused by
MSSA producing type A Bla) (2, 4, 12, 15). We have recently
shown that about 20% of MSSA clinical strains displayed an
elevated cefazolin MIC (16 g/ml) when tested at a high
inoculum (13). Here, using high-inoculum MIC determina-
tions, we determined the presence of an inoculum effect for
several cephalosporins by using a set of clinical MSSA isolates
previously classified by the type of Bla produced (13).
Ninety-eight clinical MSSA strains that have been previously
reported were included in this analysis, as follows: 25 type A,
15 type B, 45 type C, and 0 type D Bla strains and 13 blaZ-
negative strains (13). S. aureus strain TX0117, a high-level
producer of type A Bla (12); S. aureus ATCC 29213, known to
produce small amounts of type A Bla (9); and S. aureus ATCC
25923, a Bla-negative strain, were used as controls. MICs were
determined by the broth microdilution method, using the Clin-
ical and Laboratory Standards Institute (CLSI) guidelines (3).
MICs were determined using standard (5  105 CFU/ml)
and high (5  107 CFU/ml) inocula for all the tested antibi-
otics except cefuroxime (tested only at the high inoculum) and
were read at 24 h. Inocula were estimated by optical density
(OD) with random determination of CFU/ml. Ceftriaxone,
cefuroxime, cephalexin, cephalothin, and nafcillin were ob-
tained from Sigma Chemicals (Sigma, St. Louis, MO). Cefto-
biprole was provided by Johnson & Johnson Pharmaceuticals.
The MIC90s and geometric mean MICs were calculated, and
the comparisons between the geometric mean MICs of each
antibiotic among the different types of Bla-producing strains
and between the Bla-positive and Bla-negative ones were per-
formed with the nonparametric Mann-Whitney test. For all
calculations, a two-tailed P value of0.05 was considered to be
statistically significant. All statistical comparisons were per-
formed using the NCSS/PASS Dawson Edition program
(Kaysville). This study was reviewed and approved by the Duke
University Institutional Review Board.
The MICs at the high inoculum and standard inoculum of the
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five cephalosporins and nafcillin for the Bla-positive and Bla-
negative isolates are displayed in Table 1. Table 2 describes the
MICs of cephalexin, cephalothin, and ceftobiprole at the high and
standard inocula according to the type of Bla produced.
A significant increase in the MICs of cephalexin was ob-
served when Bla-positive strains were compared with Bla-neg-
ative ones. As a measure of the degree of the inoculum effect,
36.7% of the MSSA strains displayed a high-inoculum MIC of
cephalexin at above the CLSI breakpoint for nonsusceptibility
at the standard inoculum (16 g/ml). This inoculum effect
was seen with all three types of Bla-producing strains studied,
although type A and type C strains displayed higher MICs than
did type B strains. The clinical implications of these findings
are unclear since cephalexin is frequently used to treat MSSA
infections where either a high inoculum is not present or the
infection is drained. The cephalothin MICs were modestly but
significantly higher for the Bla-producing strains versus the
Bla-negative group. An increase in the high-inoculum cephalo-
thin MICs (8 g/ml) was observed in 13% of the strains, most
of which were type B and C Bla-producing strains. The differ-
ence observed in the geometric mean MICs between type B
and type C strains versus type A ones was statistically signifi-
cant. Some degree of inoculum effect for cephalothin by the
use of untyped Bla-producing isolates has been previously de-
scribed (17), and higher hydrolysis rates were observed among
type B and C Bla than those for types A and D by Zygmunt et
al. (23). In addition, lower efficacy of cephalothin was reported
in an endocarditis model with an untyped Bla-positive MSSA
strain with a high-inoculum cephalothin MIC (7).
Ceftriaxone showed the second highest geometric mean
MIC at the standard inoculum. However, the activity of ceftri-
axone was not affected by the inoculum size; at the high inoc-
ulum, one type C Bla-producing strain had a ceftriaxone MIC
of 32 g/ml, and a Bla-negative one had a ceftriaxone MIC of
16 g/ml. Ceftriaxone was as effective as cloxacillin in the
treatment of MSSA experimental endocarditis in rabbits (6)
and has been used to treat a small series of patients with MSSA
endocarditis (5) and osteomyelitis (8).
Cefuroxime was tested only at the high inoculum but did not
appear to be affected by the production of Bla since the geo-
metric mean MICs at the high inoculum of Bla-producing
strains was similar to that seen among the Bla-negative strains.
The relative stabilities of cefuroxime have been previously
described, although using few Bla-positive strains of unknown
type (18). Cefuroxime has shown similar efficacies to methicil-
lin and cefazolin in the treatment of experimental MSSA en-
docarditis (19) and appeared to have greater efficacy than
cefazolin in an endocarditis model using an MSSA strain with
high-level production of type A Bla (20).
Ceftobiprole, recently approved for clinical use in Canada
and Switzerland and advocated as a potent compound for both
MSSA and methicillin-resistant S. aureus (MRSA) isolates, has
been previously described as a poor substrate for type A Bla
(14). Here, ceftobiprole showed the lowest high- and standard-
inoculum MICs among the four types of Bla-positive strains.
However, a slight but significant difference was observed be-
tween the high-inoculum geometric mean MICs of the Bla-
positive strains and those of Bla-negative strains, suggesting
that some hydrolysis occurs.
The presence of an inoculum effect indicates a need for an
increased concentration of the tested antibiotic to achieve
growth inhibition in the presence of higher numbers of bacte-
rial cells. However, the inoculum effect is a dynamic process
where other factors are involved. For instance, a marked in-
oculum effect might not be significant in a drained infection
TABLE 2. Geometric mean MICs and MIC90s of cephalexin,
cephalothin, and ceftobiprole at high and standard inocula
according to the type of Bla produced
among MSSA strainsd
Agent Inoculum
Value (g/ml) for indicated type Bla producers:







Cephalexin SI 4.6 8 3.3 4 3.8 4
HI 14.7a,b 64 6.6a,c 16 10.6b,c 32
Cephalothin SI 0.4 0.5 0.5 1 0.6 1
HI 1.3a,b 4 3a,c 8 2b,c 8
Ceftobiprole SI 0.4 0.5 0.5 0.5 0.5 0.5
HI 0.7a,b 2 0.7a,c 1 0.7b,c 1
a For type A versus type B: cephalexin, P  0.014; cephalothin, P  0.015;
ceftobiprole, P value is not significant (NS).
b For type A versus type C: cephalexin, P  NS; cephalothin, P  0.015;
ceftobiprole, P  NS.
c For type B versus type C: cephalexin, P  0.018; cephalothin, P  NS;
ceftobiprole, P  NS.
d GM, geometric mean; SI, standard inoculum (5  105 CFU/ml); HI, high
inoculum (5  107 CFU/ml).
TABLE 1. MIC90s, geometric mean MICs, and range of MICs of
nafcillin and several cephalosporins at a high and standard








GM MIC MIC90 GM MIC MIC90
Nafcillin SI 0.4 0.5 0.4 0.5
HI 0.7a 1 0.7a 1
Cephalexin SI 3.9 4 2.5 4
HI 10.7b 32 3.1b 4
Cephalothin SI 0.5 1 0.3 0.5
HI 1.9b 8 0.3b 0.5
Ceftobiprole SI 0.4 0.5 0.3 0.5
HI 0.7b 1 0.3b 0.5
Ceftriaxone SI 2.9 4 3.1 4
HI 3.4a 4 3.1a 4
Cefuroxime HI 1a 1 1a 1
a The P value for nafcillin, ceftriaxone, and cefuroxime is 0.05. The P value
is for the GM MIC of Bla-positive strains versus the GM MIC of Bla-negative
strains.
b The P value for cephalexin, cephalothin, and ceftobiprole is 0.0001. The P
value is for the GM MIC of Bla-positive strains versus the GM MIC of Bla-
negative strains.
c GM, geometric mean; SI, standard inoculum (5  105 CFU/ml); HI, high
inoculum (5  107 CFU/ml).
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and/or when high antibiotic concentrations are achieved at the
infection site. On the other hand, a mild inoculum effect might
be significant in an infection with a high number of bacterial
cells and/or with low concentrations of the antibiotic at the
specific infection site. Considering that up to 50% of the staph-
ylococcal Bla is excreted from the bacterial cells (1), the con-
centration of this enzyme at the infection site could be consid-
erable in high-inoculum infections. In this situation, if the
infecting MSSA strain produces large amounts of an active
Bla, the enzyme may inactivate its target at a rate high enough
to overcome its antibacterial effect. An association between
cefazolin and clinical failures in patients with endocarditis (2,
4, 12, 15) caused by MSSA strains displaying an inoculum
effect with cefazolin appeared to be well documented (12, 15).
In this study, we expand the knowledge about the effects of the
different types of Bla measured by the inoculum effect on the
tested cephalosporins. Further studies are required to deter-
mine if the presence of an in vitro inoculum effect to certain
cephalosporin might affect the clinical therapeutic response in
serious MSSA infections.
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